Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Cosmo Pharmaceuticals N.V.
  6. Summary
    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
82.3(c) 81(c) 81.3(c) 81.2(c) 82.5(c) Last
6 981 9 091 6 835 5 052 11 584 Volume
+1.60% -1.58% +0.37% -0.12% +1.60% Change
More quotes
Estimated financial data (e)
Sales 2021 60,8 M 71,2 M 71,2 M
Net income 2021 5,22 M 6,12 M 6,12 M
Net cash position 2021 42,1 M 49,4 M 49,4 M
P/E ratio 2021 214x
Yield 2021 -
Sales 2022 76,1 M 89,2 M 89,2 M
Net income 2022 11,6 M 13,5 M 13,5 M
Net cash position 2022 62,6 M 73,4 M 73,4 M
P/E ratio 2022 92,9x
Yield 2022 0,19%
Capitalization 1 081 M 1 270 M 1 268 M
EV / Sales 2021 17,1x
EV / Sales 2022 13,4x
Nbr of Employees 276
Free-Float 45,1%
More Financials
Company
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline... 
Sector
Pharmaceuticals
Calendar
11/16Presentation
More about the company
Ratings of Cosmo Pharmaceuticals N.V.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about COSMO PHARMACEUTICALS N.V.
07/30COSMO PHARMACEUTICALS N : Logs Widened H1 Loss On Higher Expenses
MT
07/30EQS-ADHOC : Cosmo Half-Year Report 2021
DJ
07/30Cosmo Pharmaceuticals N.V. Reports Earnings Results for the Half Year Ended J..
CI
07/29EQS-ADHOC : Cassiopea Announces Results for First Half of 2021
DJ
07/26CASSIOPEA S P A : Enters License, Supply Deals for Acne Treatment in North Ameri..
MT
07/26EQS-ADHOC : Cosmo Pharmaceuticals Announces Cassiopea SpA's Signing of License a..
DJ
05/28COSMO PHARMACEUTICALS N : ' Shareholders approve all Agenda Items at Annual Gene..
EQ
05/28EQS-ADHOC : Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Annu..
DJ
05/10COSMO PHARMACEUTICALS N : announces a change in its board of directors
EQ
05/10Cosmo Pharmaceuticals N.V. Announces Resignation of Hans Christoph Tanner as ..
CI
04/29COSMO PHARMACEUTICALS N : Invitation to Cosmo's GI Genius Q&A session for invest..
AQ
04/21COSMO PHARMACEUTICALS N : Seeks US Approval For GI Genius Endoscopy System
MT
04/19COSMO PHARMACEUTICALS N : Lists Shares On Frankfurt's Xetra Bourse
MT
04/19COSMO PHARMACEUTICALS N : announces the start of trading of its shares on XETRA
EQ
04/13COSMO PHARMACEUTICALS N : announces FDA approval of GI Genius intelligent endosc..
AQ
More news
News in other languages on COSMO PHARMACEUTICALS N.V.
07/30Cosmo creuse ses pertes au premier semestre
07/30Cosmo kündigt nach Halbjahresverlust Gewinn für 2021 an
07/30Halbjahresbericht 2021 von Cosmo
07/30EQS-ADHOC : Halbjahresbericht 2021 von Cosmo
07/30EQS-ADHOC : Halbjahresbericht 2021 von Cosmo -2-
More news
Analyst Recommendations on COSMO PHARMACEUTICALS N.V.
More recommendations
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | COPN | NL0011832936 | MarketScreener
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 75,43 €
Average target price 97,09 €
Spread / Average Target 28,7%
EPS Revisions
Managers and Directors
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Mauro Severino Ajani Executive Chairman
Davide Malavasi Director-Qualified Person & Technical
Stefano Selva Chief Scientific Officer
H. Jurgen Lenz Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
COSMO PHARMACEUTICALS N.V.-2.94%1 270
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604